NCT06685289View on ClinicalTrials.gov

Donafenib Combined With Capecitabine for Postoperative Adjuvant Therapy of Biliary Malignant Tumors With High-risk Recurrence Risk

PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

November 15, 2024

Primary Completion Date

November 15, 2026

Study Completion Date

November 15, 2027

Conditions
Biliary Malignant Tumors
Interventions
DRUG

Donafenib

200mg, oral, twice daily, continuous medication for 6 months

DRUG

capecitabine

1250mg/m2, oral, twice daily, treatment for 2 weeks with 1 week off, with 3 weeks as a treatment cycle (a total of 8 treatment cycles)

Trial Locations (1)

210029

RECRUITING

The First Affiliated Hospital with Nanjing Medical University, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER